** Brokerage Oppenheimer says that despite BridgeBio's BBIO.O heart disease drug seeing rapid early uptake, there remains preference for competitors like Alnylam's ALNY.O Amvuttra and Pfizer's PFE.N Vyndamax
** Vyndamax remains the mainstay treatment, according to brokerage's survey
** Entry of Amvuttra may slow growth of BridgeBio's Attruby, as doctors' interest in Alnylam's drug is high
** Brokerage adds that despite the apparent preference diagnosis rates and drug access should be improved with competition, although analysts estimates look very low for near-term Attruby sales
** Analysts expect 2025 sales of $162.43 million for Attruby, according to 3 analysts as per LSEG data
** The drugs are approved for ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart, potentially causing the organ to fail
** Brokerage also sees substantial concern over the durability of sales, particularly with anticipated generic entry in 2029
** Adds that Alnylam's decision to maintain premium pricing may sway insurers to other drugs, while Attruby's lower price appears to lack strategic value for BBIO
** Up to last close, PFE down 3.7%, ALNY up 19.4% and BBIO down 33.9% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.